Drugs for Diastolic Heart Failure (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 109)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Spironolactone |
Approved |
Phase 4,Phase 3,Phase 2,Not Applicable |
|
1952-01-7, 52-01-7 |
5833
|
|
Synonyms:
4-18-00-01601 (Beilstein Handbook Reference)
496916-40-6
4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate
52-01-7
7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone
AB00513806
Abbolactone
AC1L1L8Q
AC-4214
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone (TN)
Aldactone a
Aldactone A
Alderon
Aldopur
Almatol
Alphapharm brand OF spironolactone
Alphapharm Brand of Spironolactone
Alpharma brand OF spironolactone
Alpharma Brand of Spironolactone
Alter brand OF spironolactone
Alter Brand of Spironolactone
Altex
Aquareduct
Ashbourne brand OF spironolactone
Ashbourne Brand of Spironolactone
Azupharma brand OF spironolactone
Azupharma Brand of Spironolactone
betapharm Brand of Spironolactone
Betapharm brand OF spironolactone
BIDD:PXR0071
BPBio1_000194
BRD-K90027355-001-03-4
BRN 0057767
BSPBio_000176
C07310
C24H32O4S
Cardel brand OF spironolactone
Cardel Brand of Spironolactone
CHEBI:428201
CHEBI:45692
CHEBI:9241
CHEMBL1393
CID5833
CPD000471892
ct Arzneimittel Brand of Spironolactone
CT Arzneimittel brand OF spironolactone
ct-Arzneimittel Brand of Spironolactone
CT-Arzneimittel brand OF spironolactone
D00443
D013148
DB00421
Deverol
dexo Brand OF spironolactone
Dexo Brand of Spironolactone
Diatensec
Dira
Duraspiron
EINECS 200-133-6
Espironolactona
Espironolactona [INN-Spanish]
Espironolactona alter
Espironolactona Alter
Espironolactona mundogen
Espironolactona Mundogen
Euteberol
Flumach
Frumikal
Generosan brand OF spironolactone
Generosan Brand of Spironolactone
HMS1568I18
HMS2090N21
Hormosan brand OF spironolactone
Hormosan Brand of Spironolactone
HSDB 3184
I06-1970
Jenapharm brand OF spironolactone
Jenapharm Brand of Spironolactone
Jenaspiron
Lacalmin
Lacdene
Laractone
LS-118614
LT00772287
Mayoly-spindler brand OF spironolactone
Mayoly-Spindler Brand of Spironolactone
Melarcon
Merck dura brand OF spironolactone
Merck dura Brand of Spironolactone
MLS001074672
MLS001333253
MLS001333254
|
MLS002153245
MLS002207058
Mundogen brand OF spironolactone
Mundogen Brand of Spironolactone
NCGC00164397-01
NCGC00164397-02
Nefurofan
novo Spiroton
Novo Spiroton
Novopharm brand OF spironolactone
Novopharm Brand of Spironolactone
novo-Spiroton
NovoSpiroton
Novo-Spiroton
NSC 150399
NSC150399
Osyrol
Pfizer brand OF spironolactone
Pfizer Brand of Spironolactone
Pharmafrid brand OF spironolactone
Pharmafrid Brand of Spironolactone
Practon
Prestwick0_000128
Prestwick1_000128
Prestwick2_000128
Prestwick3_000128
Roche brand OF spironolactone
Roche Brand of Spironolactone
S0260
S3378_SIGMA
Sagisal
SAM002264648
SC 9420
SC9420
SC-9420
Searle brand OF spironolactone
Searle Brand of Spironolactone
Sincomen
SMR000471892
SNL
SPBio_002115
Spiractin
Spiresis
Spiretic
Spiridon
spiro L.U.T.
Spiro L.U.T.
spiro von ct
spiro Von CT
Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan)
Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]
Spirobeta
Spiroctan
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
spirono Isis
Spirono Isis
Spironocompren
spirono-Isis
Spirono-Isis
spironolactone
Spironolactone
Spironolactone (JP15/USP/INN)
Spironolactone [BAN:INN:JAN]
Spironolactone [INN:BAN:JAN]
Spironolactone A
Spironolactonum
Spironolactonum [INN-Latin]
spironolattone
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
Spiro-Tablinen
Sprioderm
Supra-puren
Suracton
UNII-27O7W4T232
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
von ct, spiro
Von CT, spiro
WLN: L E5 B666 FX OV MUTJ A1 E1 KSV1 F-& CT5VOXTJ
Worwag Brand of Spironolactone
Wörwag brand OF spironolactone
Xenalon
ZINC03861599
|
|
| 2 |
|
Eplerenone |
Approved |
Phase 4,Phase 2,Phase 3,Not Applicable |
|
107724-20-9 |
150310
443872
|
|
Synonyms:
107724-20-9
7alpha-methoxycarbonyl-3-oxo-9,11alpha-epoxy-17alpha-pregn-4-ene-21,17-carbolactone
9,11-Epoxy-7-(methoxycarbonyl)-3-oxo-17-pregn-4-ene-21,17-carbolactone
AC1L9FDC
AC-4213
C12512
CGP-30083
CHEBI:31547
CHEBI:726453
CHEMBL1095097
CID443872
D01115
Eplerenon
Eplerenone
|
Eplerenone (JAN/USAN/INN)
Epoxymexrenone
Inspra
Inspra (TN)
Inspra, Epoxymexrenone, CGP30083, SC-66110,Eplerenone
MolPort-003-986-216
NCGC00159559-01
NCGC00159559-02
S1707_Selleck
SC-66110
Selara
TL8000270
ZINC03985982
|
|
| 3 |
|
Valsartan |
Approved, Investigational |
Phase 4,Phase 3 |
|
137862-53-4 |
60846
|
|
Synonyms:
(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
(s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid
(S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
|Tareg
137862-53-4
AC1L1U1M
AC1Q5QIK
AC-4543
Ambap137862-53-4
Aventis brand of valsartan
BIDD:GT0345
Bio-0796
BRD-K45158365-001-02-3
BSPBio_003501
C081489
C24H29N5O3
CEPA brand of valsartan
CGP 48933
CGP-48933
CHEBI:9927
CHEMBL1069
CID60846
CPD000466318
D00400
DB00177
Diovan
Diovan (TN)
Diovan, Valsartan
Esteve brand of valsartan
HMS1922L21
HMS2051L12
HMS2093K22
HSDB 7519
Kalpress
KBio2_002287
KBio2_004855
KBio2_007423
KBio3_003006
KBioGR_001078
KBioSS_002289
|
Lacer brand of valsartan
LS-161334
L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
Miten
MLS000759423
MLS001424088
MolPort-002-507-854
MolPort-003-666-608
N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
Nisis
Nisis||
Novartis brand of valsartan
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-Pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
N-Valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
Provas
S1894_Selleck
SAM001246581
Sanol brand of valsartan
Schwarz brand of valsartan
SMR000466318
SPBio_001260
Spectrum_001796
SPECTRUM1505209
Spectrum2_001120
Spectrum3_001831
Spectrum4_000749
Spectrum5_001582
Tareg
TL8000869
UNII-80M03YXJ7I
Vals
Valsarran
valsartan
Valsartan (JAN/USAN/INN)
Valsartan [USAN:INN]
walsartan
|
|
| 4 |
|
Angiotensin II |
Approved, Investigational |
Phase 4,Phase 3 |
|
68521-88-0, 4474-91-3, 11128-99-7 |
172198
65143
|
|
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
5 L Isoleucine angiotensin II
5-isoleucine-angiotensin II
5-Isoleucine-angiotensin II
5-L-Isoleucine angiotensin II
5-L-isoleucineangiotensin II
5-L-Isoleucineangiotensin II
Ang II
ANG-(1-8)octapeptide
Angiotensin
Angiotensin 2
Angiotensin II (human)
Angiotensin II (mouse)
Angiotensin II, 5-L-isoleucine
Angiotensin-(1-8) octapeptide
|
Angiotonin
Asp-arg-val-tyr-ile-his-pro-phe
Human angiotensin II
Hypertensin
II, 5-L-isoleucine angiotensin
Ile(5)-angiotensin II
Ile5-angiotensin II
Isoleucine(5)-angiotensin
Isoleucine(5)-angiotensin II
isoleucine5-angiotensin II
Isoleucyl(5)-angiotensin II
N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
Valyl(5)-angiotensin II
|
|
| 5 |
|
Regadenoson |
Approved, Investigational |
Phase 4 |
|
313348-27-5 |
219024
|
|
Synonyms:
|
| 6 |
|
Nebivolol |
Approved, Investigational |
Phase 4 |
|
152520-56-4, 99200-09-6, 118457-14-0 |
71301
|
|
Synonyms:
1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol
1,1'-[Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)]-2,2'-iminodiethanol
1,1'-Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2,2'-iminodiethanol
104365-59-5
118457-14-0
2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]
99200-09-6
a,Alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
AC-1611
AC1L2FX8
AC1Q4OMF
alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol
alpha,Alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol
alpha,alpha'-(Iminobis(methylene))bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
alpha,alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
alpha,Alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
alpha,alpha'-(iminodimethylene)bis-(6-fluoro-2-chromanmethanol)
alpha,alpha'-(Iminodimethylene)bis(6-fluoro-2-chromanmethanol)
Bystolic
C22H25F2NO4
CHEMBL434394
CID71301
D05127
DB04861
Hydrochloride, nebivolol
I06-0378
L001284
|
Lobivon
LS-178404
MolPort-003-849-343
Narbivolol
Nebicard-5
Nebilet
Nebilong
Nebipill
Nebivolol
Nebivolol (USAN/INN)
Nebivolol [USAN:INN:BAN]
Nebivolol hydrochloride
Nebivololum
nebivololum [latin]
Nebivololum [Latin]
Nodon
Nubeta
PDSP1_000244
PDSP2_000243
PI-21858
R 67555
R65,824
R-67555
Silostar
UNII-030Y90569U
α,alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
|
|
| 7 |
|
Adenosine |
Approved, Investigational |
Phase 4 |
|
58-61-7 |
60961
|
|
Synonyms:
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
1-(6-amino-9H-Purin-9-yl)-1-deoxy-beta-delta-ribofuranose
1-(6-amino-9H-Purin-9-yl)-1-deoxy-beta-D-ribofuranose
1odi
2fqy
2gl0
30143-02-3
46946-45-6
46969-16-8
4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside
58-61-7
6-Amino-9-.beta.-ribofuranosyl-9H-purine
6-amino-9-b-D-Ribofuranosyl-9H-purine
6-amino-9beta-delta-Ribofuranosyl-9H-purine
6-amino-9beta-D-Ribofuranosyl-9H-purine
6-amino-9-beta-D-Ribofuranosyl-9H-purine
6-Amino-9beta-D-ribofuranosyl-9H-purine
6-Amino-9-beta-D-ribofuranosyl-9H-purine
6-amino-9-β-D-ribofuranosyl-9H-purine
9-(beta-D-Arabinofuranosyl)adenine
9-b-D-Ribofuranosidoadenine
9-b-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyladenine
9-beta-delta-Arabinofuranosyladenine
9-beta-delta-Ribofuranosidoadenine
9beta-delta-Ribofuranosyl-9H-purin-6-amine
9-beta-delta-Ribofuranosyl-9H-purin-6-amine
9beta-delta-Ribofuranosyladenine
9-beta-delta-Ribofuranosyladenine
9-beta-D-Ribofuranosidoadenine
9beta-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Ribofuranosyl-9H-purin-6-amine
9beta-D-Ribofuranosyladenine
9-beta-D-Ribofuranosyladenine
9-β-D-ribofuranosidoadenine
9-β-D-ribofuranosyl-9H-purin-6-amine
A0152
A4036_SIGMA
A9251_SIGMA
AC1L1U8O
AC1Q1ID3
AC1Q52XU
Adenin riboside
Adenine 9-beta-D-arabinofuranoside
Adenine deoxyribonucleoside
Adenine Deoxyribonucleoside
Adenine nucleoside
Adenine riboside
Adenine-9beta-delta-ribofuranoside
Adenine-9beta-D-ribofuranoside
Adenine-9-beta-D-ribofuranoside
adenine-D-ribose
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenogesic
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosina
adenosine
Adénosine
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine, homopolymer
Adenosinum
Adensoine
Adenyldeoxyriboside
Ade-rib
Ade-Rib
|
ADN
Ado
AI3-52413
BB_NC-0565
b-D-Adenosine
beta-Adenosine
beta-D-Adenosine
beta-delta-Adenosine
beta-D-Ribofuranoside, adenine-9
Bio1_000437
Bio1_000926
Bio1_001415
bmse000061
Boniton
BSPBio_001796
C00212
Caswell No. 010B
CCRIS 2557
CHEBI:16335
CHEMBL477
CID60961
D000241
D00045
DB00640
Deoxyadenosine
Desoxyadenosine
EA6C60C2-6AFB-4264-A2F0-541373DB950E
EINECS 200-389-9
FT-0082881
HMS1920A13
HMS2091G13
KBio3_001296
LS-15085
MEDR-640
MLS000069638
MLS002153227
MolPort-001-838-229
Myocol
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
nchembio.143-comp9
nchembio.186-comp109
nchembio.2007.56-comp13
nchembio.64-comp4
nchembio706-5
NSC 627048
NSC 7652
NSC627048
NSC7652
Nucleocardyl
Pallacor
Polyadenosine
Polyriboadenosine
S1647_Selleck
Sandesin
SDCCGMLS-0003108.P003
SMR000058216
SPBio_001194
SPECTRUM1500107
Spectrum2_001257
Spectrum3_000288
SR 96225
SR-96225
SUN-Y4001
TL8003749
UNII-K72T3FS567
USAF CB-10
V0098
Vidarabine
ZINC02169830
β-D-adenosine
|
|
| 8 |
|
Furosemide |
Approved, Vet_approved |
Phase 4 |
|
54-31-9 |
3440
|
|
Synonyms:
2-furfurylamino-4-chloro-5-Sulfamoylbenzoate
2-furfurylamino-4-chloro-5-Sulfamoylbenzoic acid
2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid
2-furfurylamino-4-chloro-5-Sulphamoylbenzoate
2-furfurylamino-4-chloro-5-Sulphamoylbenzoic acid
41733-55-5 (mono-hydrochloride salt)
4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
4-chloro-5-Sulfamoyl-N-furfuryl-anthranilate
4-chloro-5-Sulfamoyl-N-furfuryl-anthranilic acid
4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid
4-chloro-5-Sulphamoyl-N-furfuryl-anthranilate
4-chloro-5-Sulphamoyl-N-furfuryl-anthranilic acid
4-chloro-N-(2-Furylmethyl)-5-sulfamoylanthranilate
4-chloro-N-(2-Furylmethyl)-5-sulfamoylanthranilic acid
4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
4-chloro-N-(2-Furylmethyl)-5-sulphamoylanthranilate
4-chloro-N-(2-Furylmethyl)-5-sulphamoylanthranilic acid
4-chloro-N-Furfuryl-5-sulfamoylanthranilate
4-chloro-N-Furfuryl-5-sulfamoylanthranilic acid
4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid
4-chloro-N-Furfuryl-5-sulphamoylanthranilate
4-chloro-N-Furfuryl-5-sulphamoylanthranilic acid
5-18-09-00555 (Beilstein Handbook Reference)
54-31-9
AB00052001
AC-11067
AC1L1FXW
AC1Q557O
Acetic acid potassium salt
Aisemide
AKOS000266625
Aldalix
Aldic
Aluzine
Anfuramaide
apo-Frusemide
Apo-Frusemide
apo-Furosemide
Apo-Furosemide
Aquarid
Aquasin
Arasemide
ARONIS24304
Beronald
BIDD:GT0139
Bio-0044
Bioretic
BPBio1_000443
BRD-K78010432-001-05-8
Bristab
Bristurin
BRN 0840915
BSPBio_000401
BSPBio_002054
C12H11ClN2O5S
CAS-54-31-9
CCRIS 1951
Cetasix
CHEBI:47426
CHEMBL35
Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure
Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]
CID3440
CPD000058202
D00331
D005665
DB00695
DB07799
Depix
Desal
Desdemin
Di-Ademil
Dihydroflumethiazide
Dirine
Disal
Discoid
Disemide
Diucardin
Diumide-K
Diural
Diurapid
Diuretic salt
Diuretic Salt
Diurin
Diurolasa
Diusemide
Diusil
Diuzol
DivK1c_000575
Dranex
Dryptal
Durafurid
Edemid
Edenol
EINECS 200-203-6
Eliur
Elodrine
Endural
Errolon
Eutensin
F0182
F4381_SIGMA
Farsix
Finuret
Fluidrol
Fluss
Franyl
Frumex
Frumide
Frumil
Frusedan
Frusema
Frusemid
Frusemide
Frusemin
Frusenex
Frusetic
Frusid
Fu sid
Fulsix
Fuluvamide
Fuluvamine
fulvamide
FUN
Furanthril
Furanthryl
Furantral
Furantril
Furanturil
Furesis
Furetic
Furex
Furfan
Furix
Furmid
furo-Basan
Furo-Basan
Furobeta
Furocot
Furodiurol
Furodrix
Furomen
Furomex
Furomide M.D
Furomide m.d.
Furomide M.D.
furo-Puren
Furo-puren
Furo-Puren
Furorese
Furosan
Furose
Furosedon
Furosemid
Furosemida
Furosemida [INN-Spanish]
furosemide
Furosemide
Furosemide "mita"
Furosemide (JP15/USP/INN)
Furosemide [USAN:INN:JAN]
furosemide ''mita''
Furosemide monohydrochloride
Furosemide Monohydrochloride
Furosemide monosodium salt
Furosemide Monosodium Salt
FUROSEMIDE USP
Furosemidu
Furosemidu [Polish]
Furosemidum
Furosemidum [INN-Latin]
Furosemix
Furoside
|
Furosifar
Furosix
Furoter
Furovite
Fursemid
Fursemida
Fursemide
Fursol
Fusid
Fusidic acid
Golan
Hissuflux
HMS1569E03
HMS1920B03
HMS2090K06
HMS2091H05
HMS501M17
Hoe-058A
HSDB 3086
Hydol
Hydrenox
Hydrex
Hydro
Hydroled
hydro-Rapid
Hydro-rapid
Hydro-Rapid
I04-0179
IDI1_000575
Impugan
Jenafusid
Katlex
KBio1_000575
KBio2_001580
KBio2_004148
KBio2_006716
KBio3_001274
KBioGR_001259
KBioSS_001580
Kofuzon
Kolkin
Kutrix
Lasemid
Lasex
Lasiletten
Lasilix
Lasix
Lasix (tn)
Lasix (TN)
Lasix retard
Lasix Retard
Lasix Special
Lasix, Frusemide, Furosemide
Laxur
Lazix
LB 502
LB-502
Leodrine
less Diur
Less diur
Less Diur
Liside
Logirene
Lowpston
Lowpstron
LS-204
Luscek
Macasirool
Marsemide
Metflorylthiazidine
Methforylthiazidine
Mirfat
Mita
MLS001066374
MLS001306403
Moilarorin
MolPort-001-641-065
Myrosemide
Nadis
NCGC00016241-01
NCGC00090893-01
NCGC00090893-02
NCGC00090893-03
NCGC00090893-05
NCGC00090893-06
NCI-C55936
Nelsix
neo-Renal
Neo-renal
Neo-Renal
Nephron
Nicorol
NINDS_000575
Novosemide
NSC 269420
NSC269420
Octan draselny
Octan Draselny
Odemase
Odemex
Oedemex
Olmagran
Oprea1_667724
Osyrol
Polysquall a
Polysquall A
Prefemin
Prestwick_752
Prestwick0_000341
Prestwick1_000341
Prestwick2_000341
Prestwick3_000341
Profemin
Promedes
Promide
Protargen
Puresis
Radisemide
Radonna
Radouna
Retep
Rodiuran
Rontyl
Rosemide
Rosis
Rusyde
S1603_Selleck
Sal diureticum
Sal Diureticum
Salinex
Salix
Salix (brand of furosemide)
Salix (brand OF furosemide)
Salurex
Salurid
Saluron
SAM002264614
Seguril
Selectofur
Sigasalur
Sisuril
SMP1_000129
SMR000058202
SPBio_001129
SPBio_002322
Spectrum_001100
SPECTRUM1500310
Spectrum2_001005
Spectrum3_000437
Spectrum4_000560
Spectrum5_000744
Spirofur
STK177334
Synephron
TL8003563
Transit
Trofurit
UNII-7LXU5N7ZO5
UPCMLD-DP022
UPCMLD-DP022:001
Uremide
Uresix
Urex
Urex-m
Urex-M
Urian
Uridon
Uritol
Urosemide
Vergonil
Vesix
WLN: T5OJ B1MR CG FVQ DSZW
Yidoli
Zafimida
|
|
| 9 |
|
Dopamine |
Approved |
Phase 4 |
|
51-61-6, 62-31-7 |
681
|
|
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
| 10 |
|
Exenatide |
Approved, Investigational |
Phase 4 |
|
141758-74-9 |
15991534
|
|
Synonyms:
141732-76-5
141758-74-9
286014-72-0
335149-21-8
AC 2993
AC 2993 LAR
AC 2993A
AC002993
AC2993
AC-2993
AC2993a
Byetta
C074031
|
CHEBI:490990
CHEMBL414357
Ex4 peptide
Exenatide
Exenatide synthetic
Exenatide Synthetic
Exendin 4
Exendin 4 (Heloderma suspectum)
Exendin-4
Extendin-4
LY2148568
Synthetic exendin-4
UNII-9P1872D4OL
|
|
| 11 |
|
Estradiol valerate |
Approved, Investigational, Vet_approved |
Phase 4 |
|
979-32-8 |
|
| 12 |
|
Estradiol |
Approved, Investigational, Vet_approved |
Phase 4 |
|
50-28-2 |
5757
|
|
Synonyms:
(+)-3,17b-Estradiol
(17b)-Estra-1,3,5(10)-triene-3,17-diol
(17beta)-Estra-1,3,5(10)-triene-3,17-diol
(17β)-estra-1,3,5(10)-triene-3,17-diol
.alpha.-Estradiol
.alpha.-Oestradiol
.beta.-Estradiol
.beta.-Oestradiol
[2,4,6,7-3H]-E2
[3H]]estradiol
[3H]-estradiol
13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol
17 beta Estradiol
17 beta Oestradiol
17 beta-Estradiol
17 beta-Oestradiol
17.beta.-Estradiol
17-.BETA.-Estradiol
17.beta.-Oestradiol
17b Oestradiol
17b-Estra-1,3,5(10)-triene-3,17-diol
17b-Estradiol
17-beta
17beta oestradiol
17beta Oestradiol
17beta-Estra-1,3,5(10)-triene-3,17-diol
17-beta-estradiol
17beta-Estradiol
17beta-Oestradiol
17-beta-OH-estradiol
17b-Oestradiol
17E
17-E
17β oestradiol
17β-estra-1,3,5(10)-triene-3,17-diol
17β-estradiol
17β-oestradiol
1jgl
1qkt
1qku
2d06
3,17.beta.-Estradiol
3,17b-Dihydroxyestra-1,3,5(10)-triene
3,17b-Estradiol
3,17beta-Estradiol
3,17-beta-Estradiol
3,17-beta-Oestradiol
3,17-Epidihydroxyestratriene
50-28-2
73459-61-7
873662-39-6
AC-10460
AC1L1L2K
Aerodiol
Agofollin
Alora
Altrad
Amnestrogen
Aquadiol
Bardiol
b-Estradiol
B-Estradiol
beta-Estradiol
Beta-estradiol
BIDD:ER0125
BIDD:PXR0065
Bio-0812
Bio1_000403
Bio1_000892
Bio1_001381
Bio2_000363
Bio2_000843
Bio-E-Gel
bmse000642
BPBio1_000532
BSPBio_000482
BSPBio_001065
C00951
C18H24O2
CCRIS 280
CHEBI:16469
CHEMBL135
CID5757
cis-Estradiol
cis-Oestradiol
Climaderm
Climara
Climara (TN)
Climara Forte
cMAP_000005
CMC_11154
component of Menrium
Compudose
Compudose 200
Compudose 365
Corpagen
CPD000059126
CPD-352
D00105
D-3,17beta-Estradiol
DB00783
delta-Estradiol
delta-Oestradiol
Dermestril
Destradiol
D-Estradiol
Dihydrofollicular hormone
Dihydrofolliculin
Dihydromenformon
dihydro-Theelin
Dihydrotheelin
Dihydroxyesterin
Dihydroxyestrin
Dihydroxyoestrin
Dimenformon
Diogyn
Diogynets
Divigel
Divigel (TN)
D-Oestradiol
E 2
E 8875
E(sub 2)
E0025
E1024_SIGMA
E1132_SIGMA
E2257_SIGMA
E2758_SIGMA
E8875_SIGMA
EINECS 200-023-8
Elestrin
Encore
Epiestriol 50
Esclim
Estra-1,3,5(10)-triene-3,17b-diol
Estrace
Estrace (TN)
Estraderm
Estraderm (TN)
Estraderm MX
Estraderm TTS
Estraderm TTS 100
Estraderm TTS 50
estradiol
Estradiol
Estradiol [USAN:INN]
Estradiol 17 alpha
Estradiol 17 beta
Estradiol 17beta
Estradiol anhydrous
Estradiol hemihydrate
Estradiol hemihydrate, (17 alpha)-isomer
Estradiol monohydrate
Estradiol orion brand
Estradiol, (-)-isomer
Estradiol, (+-)-isomer
Estradiol, (16 alpha,17 alpha)-isomer
Estradiol, (16 alpha,17 beta)-isomer
Estradiol, (17-alpha)-isomer
Estradiol, (8 alpha,17 beta)-(+-)-isomer
Estradiol, (8 alpha,17 beta)-isomer
Estradiol, (9 beta,17 alpha)-isomer
Estradiol, (9 beta,17 beta)-isomer
Estradiol, monosodium salt
Estradiol, sodium salt
Estradiol-17 alpha
Estradiol-17 beta
Estradiol-17.beta.
Estradiol-17b
|
estradiol-17beta
Estradiol-17beta
Estradiol-17-beta
Estradiol-17β
Estradiol-3,17beta
Estradiolo
Estradiolo [DCIT]
Estradiolum
Estradiolum [INN]
Estradot
Estraldine
Estrapak 50
Estrasorb
Estrasorb (TN)
Estreva
Estrifam
Estring
Estring (TN)
Estring vaginal ring
Estroclim
Estroclim 50
Estrodiolum
Estrofem 2
Estrofem Forte
Estrogel
Estrogel (TN)
Estrogel HBF
Estrovite
EU-0100503
Evamist
Evorel
Extrasorb
Femanest
Femestral
Femestrol
Femogen
Fempatch
Femtrace
Femtran
Follicyclin
Gelestra
Ginedisc
Ginosedol
Gynergon
Gynestrel
Gynodiol
Gynoestryl
GynPolar
HMS1362E07
HMS1569I04
HMS1792E07
HMS1990E07
HMS2051C17
HMS2090E18
HSDB 3589
IDI1_002118
Innofem
Innofem (TN)
KBio2_000405
KBio2_002269
KBio2_002973
KBio2_004837
KBio2_005541
KBio2_007405
KBio3_000769
KBio3_000770
KBio3_002749
KBioGR_000405
KBioGR_002269
KBioSS_000405
KBioSS_002270
Lamdiol
LMST02010001
Lopac0_000503
LS-137
Macrodiol
Macrol
Menest
Menorest
Microdiol
MLS000069494
MLS000758312
MLS001076331
MolPort-001-794-632
NCGC00091544-00
NCGC00091544-01
NCGC00091544-02
NCGC00091544-04
NCGC00091544-05
NCGC00091544-06
NCGC00091544-07
NCGC00091544-08
NCGC00091544-09
NCGC00091544-12
NCGC00179321-01
NCGC00179321-02
nchembio.168-comp3
nchembio.76-comp2
nchembio775-comp2
nchembio794-comp6
nchembio860-comp1
Nordicol
Novartis pharmaceuticals brand OF estradiol
NSC9895
NSC-9895
Oesclim
Oestergon
Oestra-1,3,5(10)-triene-3,17b-diol
Oestradiol
Oestradiol Berco
Oestradiol R
Oestradiol-17.beta.
Oestradiol-17beta
Oestradiol-17-beta
Oestradiolum
Oestrogel
Oestroglandol
Oestrogynal
Orion brand OF estradiol
Ovahormon
Ovasterol
Ovastevol
Ovociclina
Ovocyclin
Ovocycline
Ovocylin
Perlatanol
Polyestradiol
Prestwick_207
Prestwick0_000441
Prestwick1_000441
Prestwick2_000441
Prestwick3_000441
Primofol
Profoliol
Profoliol b
Profoliol B
progynon
Progynon
Progynon DH
Progynon-DH
S1709_Selleck
S-21400
SAM001247032
Sandrena 1
Sandrena Gel
Sisare Gel
SK-Estrogens
SL-1100
SMP1_000121
SMR000059126
SPBio_002421
Spectrum5_002055
Syndiol
Systen
Tradelia
Trial SAT
Trocosone
UNII-4TI98Z838E
Vagifem
Vagifem (TN)
Vivelle
Vivelle (TN)
VIVELLE-DOT
Zerella
Zesteem
Zesteen
Zumenon
β-estradiol
|
|
| 13 |
|
Norethindrone |
Approved |
Phase 4 |
|
68-22-4 |
6230
|
|
Synonyms:
(17a)-17-Ethynyl-17-hydroxyestra-4,8(14),9-trien-3-one
(17alpha)-17-Ethynyl-17-hydroxyestra-4,8(14),9-trien-3-one
(17-alpha)-17-Hydroxy-19-norpregn-4-en-20-yn-3-one
(17α)-17-ethynyl-17-hydroxyestra-4,8(14),9-trien-3-one
17.alpha.-Ethinyl-19-nortestosterone
17.alpha.-Ethynyl-19-nortestosterone
17.alpha.-Ethynyl-4-estren-17-ol-3-one
17a-Ethinyl-19-nortestosterone
17a-Ethinylestra-4-en-17b-ol-3-one
17a-Ethynyl-17b-hydroxy-19-norandrost-4-en-3-one
17a-Ethynyl-17-hydroxy-4-estren-3-one
17-a-Ethynyl-17-hydroxy-4-estren-3-one
17a-Ethynyl-19-nor-4-androsten-17b-ol-3-one
17a-Ethynyl-19-norandrost-4-en-17b-ol-3-one
17-a-Ethynyl-19-norandrost-4-en-17-b-ol-3-one
17a-Ethynyl-19-nortestosterone
17-a-Ethynyl-19-nortestosterone
17a-Ethynyl-4-estren-17-ol-3-one
17-a-Ethynyl-4-estren-17-ol-3-one
17alpha-Ethinyl-17alpha-ethinyl-19-nortestosterone
17alpha-Ethinyl-19-nortestosterone
17alpha-Ethinylestra-4-en-17beta-ol-3-one
17alpha-Ethynyl-17beta-hydroxy-19-norandrost-4-en-3-one
17-alpha-Ethynyl-17-beta-hydroxy-4-estren-3-one
17alpha-Ethynyl-17beta-hydroxyestr-4-en-3-one
17alpha-Ethynyl-17-hydroxy-4-estren-3-one
17-alpha-Ethynyl-17-hydroxy-4-estren-3-one
17alpha-Ethynyl-17-hydroxyest-4-en-3-one
17alpha-Ethynyl-17-hydroxy-estr-4-en-3-one
17alpha-Ethynyl-19-nor-4-androsten-17beta-ol-3-one
17alpha-Ethynyl-19-norandrost-4-en-17beta-ol-3-one
17-alpha-Ethynyl-19-norandrost-4-en-17-beta-ol-3-one
17alpha-Ethynyl-19-nortestosterone
17-alpha-Ethynyl-19-nortestosterone
17alpha-Ethynyl-3-oxo-4-estren-17beta-ol
17alpha-Ethynyl-4-estren-17-ol-3-one
17-alpha-Ethynyl-4-estren-17-ol-3-one
17alpha-Pregn-4-en-20-yn-3-one
17beta-Hydroxy-17alpha-ethynylestr-4-en-3-one
17beta-Hydroxy-19-norpregn-4-en-20-yn-3-one
17-beta-Hydroxy-19-norpregn-4-en-20-yn-3-one
17b-Hydroxy-19-norpregn-4-en-20-yn-3-one
17-b-Hydroxy-19-norpregn-4-en-20-yn-3-one
17-Ethinyl-19-nortestosterone
17-Ethinyl-19-nor-testosterone
17-ethynyl-17beta-hydroxyestr-4-en-3-one
17-Ethynyl-17beta-hydroxyestr-4-en-3-one
17-Ethynyl-17-hydroxyestr-4-en-3-one
17-Ethynyl-17-hydroxyestr-4-en-3-one (acd/name 4.0)
17-Ethynyl-19-nortestosterone
17-Hydroxy-(17alpha)-19-norpregn-4-en-20-yn-3-one
17-Hydroxy-17-alpha-19-norpregn-4-en-20-yn-3-one
17-Hydroxy-19-nor-17alpha-pregn-4-en-20-yn-3-one
17-Hydroxy-19-nor-17-alpha-pregn-4-en-20-yn-3-one
17-Hydroxy-19-nor-17a-pregn-4-en-20-yn-3-one
17-Hydroxy-19-nor-17-a-pregn-4-en-20-yn-3-one
17-Hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one
17-Hydroxy-19-nor-17-α-pregn-4-en-20-yn-3-one
17α-ethinyl-19-nortestosterone
17α-ethinylestra-4-en-17β-ol-3-one
17α-ethynyl-17-hydroxy-4-estren-3-one
17-α-ethynyl-17-hydroxy-4-estren-3-one
17α-ethynyl-17β-hydroxy-19-norandrost-4-en-3-one
17α-ethynyl-19-nor-4-androsten-17β-ol-3-one
17α-ethynyl-19-norandrost-4-en-17β-ol-3-one
17-α-ethynyl-19-norandrost-4-en-17-β-ol-3-one
17α-ethynyl-19-nortestosterone
17-α-ethynyl-19-nortestosterone
17α-ethynyl-4-estren-17-ol-3-one
17-α-ethynyl-4-estren-17-ol-3-one
17β-hydroxy-19-norpregn-4-en-20-yn-3-one
17-β-hydroxy-19-norpregn-4-en-20-yn-3-one
19-Nor-17.alpha.-ethynyltestosterone
19-Nor-17a-ethynyl-17b-hydroxy-4-androsten-3-one
19-Nor-17-a-ethynyl-17-b-hydroxy-4-androsten-3-one
19-Nor-17a-ethynylandrosten-17b-ol-3-one
19-Nor-17-a-ethynylandrosten-17-b-ol-3-one
19-Nor-17a-ethynyltestosterone
19-Nor-17-a-ethynyltestosterone
19-Nor-17alpa-ethynyltestosterone
19-Nor-17alpha-ethynyl-17beta-hydroxy-4-androsten-3-one
19-Nor-17-alpha-ethynyl-17-beta-hydroxy-4-androsten-3-one
19-Nor-17alpha-ethynylandrosten-17beta-ol-3-one
19-Nor-17-alpha-ethynylandrosten-17-beta-ol-3-one
19-Nor-17alpha-ethynyltestosterone
19-Nor-17-alpha-ethynyltestosterone
19-Nor-17-ethinyl testosterone
19-Nor-17-ethinyltestosterone
19-Nor-17α-ethynyl-17β-hydroxy-4-androsten-3-one
19-Nor-17-α-ethynyl-17-β-hydroxy-4-androsten-3-one
19-Nor-17α-ethynylandrosten-17β-ol-3-one
19-Nor-17-α-ethynylandrosten-17-β-ol-3-one
19-nor-17α-ethynyltestosterone
19-Nor-17α-ethynyltestosterone
19-Nor-17-α-ethynyltestosterone
19-Norethindrone
19-Nor-ethindrone
19-Nor-ethinyl--4,5-testosterone
19-Norethinyltestosterone
19-Norethisterone
46525_FLUKA
46525_RIEDEL
4-Estren-17a-ethynyl-17b-ol-3-one
4-Estren-17alpha-ethynyl-17beta-ol-3-one
4-Estren-17α-ethynyl-17β-ol-3-one
68-22-4
A3564/0151191
AC-11100
AC1L1IDS
AC1L1M2R
AC1NWAOX
AC1O5EOU
AC1Q6OG5
Activella
AI3-26422
AKOS004119895
Anhydrohydroxynorprogesterone
Anovulatorio
Anovule
AR-1C1071
ARONIS24281
BB_NC-0600
BPBio1_000074
BRD-A39415247-001-02-1
BRD-K92073408-001-03-3
Brevicon
Brevinor
Brevinor 21
Brevinor 28
Brevinor-1 21
Brevinor-1 28
BRN 1915671
BSPBio_000066
BSPBio_002101
C05028
Camila
Camila (TN)
CCRIS 484
CHEBI:7627
CHEMBL1162
Ciclovulan
CID4536
CID5702093
CID6230
CID6432649
component of Noriday
Conceplan
Conludaf
Conludag
CPD000499579
D00182
DB00717
Demulen
DivK1c_000553
EINECS 200-681-6
|
ENT
Errin
Estrinor
Ethinyl-19-nortestosterone
Ethinylnortestosterone
Ethynylmortestosterone
Ethynylnortestosterone
Gencept
Genora
Gestest
HMS1568D08
HMS1920B10
HMS2090D21
HMS2091J10
HMS501L15
HSDB 3370
I06-0104
IDI1_000553
Jenest
Jenest-28
KBio1_000553
KBio2_001491
KBio2_004059
KBio2_006627
KBio3_001601
KBioGR_000637
KBioSS_001491
LMST02030097
Loestrin
LS-97425
Menzol
Microneth
Micronett
Micronor
Micronor (TN)
Micronovum
Milli
Mini-pe
Mini-Pe
Mini-pill
Minovlar
MLS001076679
MLS001163874
MLS001304093
MolPort-002-507-131
MolPort-002-509-542
MolPort-002-728-977
MolPort-003-861-444
Monogest
N.E.E
N.E.E.
N0449
N4128_SIGMA
NCGC00178820-01
NCGC00179669-01
Nelova
NET
NINDS_000553
Nodiol
Nor QD
Nora-BE
Noraethisteronum
Noralutin
Norcept
Norcept-E
Norcolut
Norcolute
Noresthisterone
Norethadrone
Norethin
Norethin 1/35 E
Norethin 1/50 M
Norethindirone
norethindrone
Norethindrone
Norethindrone (USP)
Norethindrone [USAN]
Norethindrone Norethisterone
Norethindrone, (1 beta)-isomer
Norethisteron
Norethisterone
Norethisterone (JP15)
Norethisterone [Progestins]
Norethisteronum
Norethisteronum [INN-Latin]
Norethyndron
Norethynodron
Norethynodrone
Noretisterona
Noretisterona [INN-Spanish]
Noretisterone
Noretisterone [DCIT]
Norfor
Norgestin
Noriday
Noriday 28
Norlutate
Norluten
Norlutin
Norluton
Normapause
Norpregneninlone
Norpregneninolone
Norpregneninotone
Nor-Q.D
Nor-q.d.
Nor-Q.D.
NorQD
Nor-QD
NSC9564
NSC-9564
Oprea1_606355
Orlest
Ortho 1 35
Ortho 7 7 7
Ortho-Novum 1 35
Ortho-Novum 1 50
Ortho-Novum 7 7 7
Ovysmen 0.5 35
Ovysmen 1 35
Prestwick_646
Prestwick0_000253
Prestwick1_000253
Prestwick2_000253
Prestwick3_000253
Primolut N
Primolut-N
Primolut-N (TN)
Proluteasi
SAM002564223
SC 4640
SMR000499579
SMR000718762
SPBio_001052
SPBio_002285
Spectrum_001011
SPECTRUM1500437
Spectrum2_001066
Spectrum3_000521
Spectrum4_000079
Spectrum5_001198
ST094767
STK730956
STOCK1N-04274
Synphase
Synphasic 28
Triella
Tri-Norinyl
Trinovum 21
UNII-T18F433X4S
Utovlan
Utovlar
WLN: L E5 B666 OV MUTJ E FQ F1UU1 -A&F
ZINC03814419
|
|
| 14 |
|
Polyestradiol phosphate |
Approved |
Phase 4 |
|
28014-46-2 |
|
|
Synonyms:
(17-beta)-Estra-1,3,5(10)-triene-3,17-diol polymer with phosphoric acid
Estradiol phosphate polymer
Fosfato de poliestradiol
Oestradiol phosphate polymer
|
Phosphate de polyestradiol
Poly(estradiol phosphate)
Polyestradioli phosphas
|
|
| 15 |
|
Citric Acid |
Approved, Nutraceutical, Vet_approved |
Phase 4,Phase 3,Phase 2 |
|
77-92-9 |
311
|
|
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citretten
|
Citric acid monohydrate
Citric acid, anhydrous
Citric Acid, Anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
H3Cit
Hydrocerol a
Kyselina citronova
Monohydrate, citric acid
Suby g
Uralyt u
uro-Trainer
|
|
| 16 |
|
Atorvastatin Calcium |
|
Phase 4,Not Applicable |
|
134523-03-8 |
|
| 17 |
|
Natriuretic Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 18 |
|
Hormones |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 19 |
|
Diuretics, Potassium Sparing |
|
Phase 4,Phase 3,Phase 2,Not Applicable |
|
|
|
| 20 |
|
Vasodilator Agents |
|
Phase 4,Phase 3,Phase 2,Not Applicable |
|
|
|
| 21 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 4,Not Applicable |
|
|
|
| 22 |
|
Hypolipidemic Agents |
|
Phase 4,Not Applicable |
|
|
|
| 23 |
|
Phosphodiesterase 5 Inhibitors |
|
Phase 4,Phase 3,Phase 2 |
|
|
|
| 24 |
|
Phosphodiesterase Inhibitors |
|
Phase 4,Phase 3,Phase 2,Not Applicable |
|
|
|
| 25 |
|
Anticholesteremic Agents |
|
Phase 4,Not Applicable |
|
|
|
| 26 |
|
Lipid Regulating Agents |
|
Phase 4,Not Applicable |
|
|
|
| 27 |
|
Antimetabolites |
|
Phase 4,Not Applicable |
|
|
|
| 28 |
|
Calcium, Dietary |
|
Phase 4,Phase 2,Not Applicable |
|
|
|
| 29 |
|
Sildenafil Citrate |
|
Phase 4,Phase 3,Phase 2 |
|
171599-83-0 |
|
| 30 |
|
diuretics |
|
Phase 4,Phase 3,Phase 2,Not Applicable |
|
|
|
| 31 |
|
Mineralocorticoid Receptor Antagonists |
|
Phase 4,Phase 3,Phase 2,Not Applicable |
|
|
|
| 32 |
|
Mineralocorticoids |
|
Phase 4,Phase 3,Phase 2,Not Applicable |
|
|
|
| 33 |
|
Adrenergic beta-Antagonists |
|
Phase 4,Not Applicable |
|
|
|
| 34 |
|
Natriuretic Peptide, Brain |
|
Phase 4,Phase 1,Phase 2,Not Applicable |
|
|
|
| 35 |
|
Hormone Antagonists |
|
Phase 4,Phase 3,Phase 2,Not Applicable |
|
|
|
| 36 |
|
Angiotensin II Type 1 Receptor Blockers |
|
Phase 4,Phase 3 |
|
|
|
| 37 |
|
Angiotensin Receptor Antagonists |
|
Phase 4,Phase 3 |
|
|
|
| 38 |
|
Angiotensinogen |
|
Phase 4,Phase 3 |
|
|
|
| 39 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 4,Phase 3,Phase 2,Not Applicable |
|
|
|
| 40 |
|
Peripheral Nervous System Agents |
|
Phase 4,Phase 1 |
|
|
|
| 41 |
|
Hypoglycemic Agents |
|
Phase 4,Not Applicable |
|
|
|
| 42 |
|
Antihypertensive Agents |
|
Phase 4,Phase 3,Not Applicable |
|
|
|
| 43 |
|
Protective Agents |
|
Phase 4,Phase 1,Not Applicable |
|
|
|
| 44 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
| 45 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
| 46 |
|
Adrenergic beta-Agonists |
|
Phase 4 |
|
|
|
| 47 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
| 48 |
|
Sodium Potassium Chloride Symporter Inhibitors |
|
Phase 4 |
|
|
|
| 49 |
|
Dopamine Agents |
|
Phase 4 |
|
|
|
| 50 |
|
Autonomic Agents |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 122)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis Patients |
Unknown status |
NCT01503671
|
Phase 4 |
Atorvastatin |
| 2 |
Novel Treatment for Diastolic Heart Failure in Women |
Completed |
NCT00206232
|
Phase 4 |
Spironolactone |
| 3 |
Aldosterone Antagonism in Diastolic Heart Failure |
Completed |
NCT00108251
|
Phase 4 |
Eplerenone;Placebo |
| 4 |
A Trial of Fimasartan for Early Diastolic Heart Failure |
Completed |
NCT01691118
|
Phase 4 |
Fimasartan;Antihypertensive treatment |
| 5 |
Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart |
Completed |
NCT01944384
|
Phase 4 |
aldactone |
| 6 |
Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure |
Completed |
NCT00171106
|
Phase 4 |
valsartan |
| 7 |
SIDAMI - Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (AMI) |
Completed |
NCT01046838
|
Phase 4 |
Sildenafil;Placebo |
| 8 |
Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure |
Recruiting |
NCT02053246
|
Phase 4 |
Nebivolol |
| 9 |
Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF |
Recruiting |
NCT02589977
|
Phase 4 |
regadenoson |
| 10 |
Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction |
Active, not recruiting |
NCT01901809
|
Phase 4 |
Furosemide;Dopamine |
| 11 |
Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction |
Not yet recruiting |
NCT03506412
|
Phase 4 |
Entrestoâ„¢ 49Mg-51 mg tablet |
| 12 |
Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure |
Terminated |
NCT00293150
|
Phase 4 |
Eplerenone |
| 13 |
Use of Nesiritide in the Management of Acute Diastolic Heart Failure |
Terminated |
NCT00083772
|
Phase 4 |
Nesiritide |
| 14 |
Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan |
Terminated |
NCT00840463
|
Phase 4 |
Ambrisentan |
| 15 |
Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure |
Terminated |
NCT00799435
|
Phase 4 |
Exenatide |
| 16 |
Estrogen Diastolic Heart Failure |
Terminated |
NCT02693002
|
Phase 4 |
Estradiol/Norethindrone acetate;Placebo |
| 17 |
Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction |
Unknown status |
NCT01583881
|
Phase 2, Phase 3 |
|
| 18 |
A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF] |
Unknown status |
NCT01599117
|
Phase 3 |
Placebo;Udenafil (Zydena) |
| 19 |
Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study) |
Completed |
NCT00763867
|
Phase 3 |
Placebo;Sildenafil |
| 20 |
Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure |
Completed |
NCT01156636
|
Phase 2, Phase 3 |
Sildenafil;Placebo |
| 21 |
Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure |
Completed |
NCT01411735
|
Phase 3 |
Enalapril;placebo |
| 22 |
PIE II: Pharmacological Intervention in the Elderly II |
Completed |
NCT00123955
|
Phase 3 |
Spironolactone;Placebo |
| 23 |
Safety and Efficacy of Bosentan in Patients With Diastolic Heart Failure and Secondary Pulmonary Hypertension |
Completed |
NCT00820352
|
Phase 3 |
bosentan;placebo |
| 24 |
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function |
Completed |
NCT00094302
|
Phase 3 |
Spironolactone;Placebo |
| 25 |
Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH |
Completed |
NCT01726049
|
Phase 3 |
Sildenafil;Placebo |
| 26 |
Novel Cardiac Rehabilitation in Patients Heart Failure and Preserved Ejection Fraction |
Recruiting |
NCT02762825
|
Phase 3 |
|
| 27 |
Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years) |
Recruiting |
NCT02425371
|
Phase 3 |
|
| 28 |
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction |
Active, not recruiting |
NCT01920711
|
Phase 3 |
LCZ696;Valsartan |
| 29 |
Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer |
Terminated |
NCT01708798
|
Phase 2, Phase 3 |
Eplerenone;Placebo |
| 30 |
Study of Nesiritide in Diastolic Heart Failure. |
Completed |
NCT00309868
|
Phase 1, Phase 2 |
neseritide |
| 31 |
A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure |
Completed |
NCT00303498
|
Phase 2 |
Sitaxsentan sodium;Placebo |
| 32 |
The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure |
Completed |
NCT00043836
|
Phase 2 |
ALT-711 |
| 33 |
Ranolazine in Diastolic Heart Failure |
Completed |
NCT01163734
|
Phase 2 |
Ranolazine |
| 34 |
Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome |
Completed |
NCT00839228
|
Phase 2 |
Perhexiline;Placebo |
| 35 |
Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF |
Completed |
NCT02256345
|
Phase 2 |
KNO3;KCl |
| 36 |
Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction |
Completed |
NCT00387621
|
Phase 1, Phase 2 |
Nesiritide;Placebo;Saline |
| 37 |
Interleukin-1 Blockade in HF With Preserved EF |
Completed |
NCT02173548
|
Phase 2 |
Anakinra;Placebo |
| 38 |
Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function |
Completed |
NCT01182805
|
Phase 1, Phase 2 |
|
| 39 |
CoQ10 and D-ribose in Patients With Diastolic Heart Failure |
Recruiting |
NCT03133793
|
Phase 2 |
CoQ10;D-Ribose Oral Powder |
| 40 |
Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs |
Recruiting |
NCT02941705
|
Phase 2 |
|
| 41 |
Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I) |
Terminated |
NCT00662116
|
Phase 2 |
alagebrium;placebo |
| 42 |
A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure |
Terminated |
NCT01913301
|
Phase 2 |
Alagebrium |
| 43 |
The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure |
Terminated |
NCT01887353
|
Phase 2 |
Ranolazine;Placebo |
| 44 |
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction |
Terminated |
NCT01172756
|
Phase 2 |
Riociguat (BAY63-2521);Riociguat (BAY63-2521);Riociguat (BAY63-2521);Placebo |
| 45 |
If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure |
Withdrawn |
NCT00757055
|
Phase 2 |
Ivabradine;Placebo |
| 46 |
BNP Testing in Patients With SOB on Presentation to ED |
Unknown status |
NCT00163709
|
Phase 1 |
|
| 47 |
Physiological Effects of Grape Seed Extract in Diastolic Heart Failure |
Completed |
NCT01185067
|
Phase 1 |
grape seed extract (MegaNatural BP, Polyphenolics, Inc.) |
| 48 |
Diastolic Heart Failure Management by Nifedipine |
Unknown status |
NCT01157481
|
Not Applicable |
Conventional therapy plus nifedipine;Conventional therapy |
| 49 |
Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure |
Unknown status |
NCT00939640
|
Not Applicable |
|
| 50 |
LEft Atrial Pacing in Diastolic Heart Failure |
Unknown status |
NCT01618981
|
Not Applicable |
|
|
